 COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease CKD and can ultimately lead to end-stage renal failure - Opaganib is a novel, late clinical-stage oral pill drug candidate with dual anti-inflammatory and antiviral activity and has already demonstrated strong inhibition against variants of concern, including Delta - The global 475-patient Phase 23 study with opaganib oral pill in hospitalized COVID-19 patients has completed treatment and follow up phase, with top-line results upcoming TEL AVIV, ISRAEL and RALEIGH, NC ACCESSWIRE September 7, 2021 RedHill Biopharma Ltd. NASDAQ:RDHL RedHill or the Company, a specialty biopharmaceutical company, today announced results of a new preclinical study demonstrating opaganibs ABC2946401 efficacy in significantly decreasing renal fibrosis in a unilateral ureteral obstruction-induced renal interstitial fibrosis model. 